Your shopping cart is currently empty

DO-264 is an inhibitor of autohydrolase structural domain 12 (ABHD12) (IC50: 11 nM) and an inhibitor of cellular LysoPS degradation that enhances LPS-induced phagocytosis.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $52 | - | In Stock | |
| 5 mg | $123 | In Stock | In Stock | |
| 10 mg | $198 | - | In Stock | |
| 25 mg | $438 | - | In Stock | |
| 50 mg | $745 | - | In Stock | |
| 100 mg | $1,050 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $148 | - | In Stock |
| Description | DO-264 is an inhibitor of autohydrolase structural domain 12 (ABHD12) (IC50: 11 nM) and an inhibitor of cellular LysoPS degradation that enhances LPS-induced phagocytosis. |
| Targets&IC50 | ABHD12:11 nM |
| In vitro | DO-264 elevated the lyso-PS and 20:4 PS content of primary human macrophages[1]. |
| In vivo | Mice treated with DO-264 exhibited a dose-dependent increase in brain lyso-PS and 20:4 PS content, which qualitatively resembled changes observed in ABHD12(-/-) mice. Additionally, both ABHD12(-/-) and DO-264-treated mice displayed exacerbated immunopathology following infection with the lymphocytic choriomeningitis virus (LCMV) clone 13, resulting in severe inflammatory lung damage, heightened chemokine production, and, in some cases, death.[1]. |
| Molecular Weight | 558.4 |
| Formula | C23H20Cl2F3N5O2S |
| Cas No. | 2301866-59-9 |
| Smiles | FC(F)(F)Oc1ccc(Oc2ccnc(N3CCC(CC3)NC(=S)Nc3cccnc3)c2Cl)c(Cl)c1 |
| Relative Density. | 1.52 g/cm3 (Predicted) |
| Storage | store under nitrogen,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (143.27 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (5.91 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.